BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3550283)

  • 1. [Extracardiac systemic pharmacodynamic effects of estulic (guanfacine)].
    Kukes VG; Spasskiĭ AV; Tsoĭ AN; Blinkov IL; Karpenko EV
    Klin Med (Mosk); 1987 Jan; 65(1):46-9. PubMed ID: 3550283
    [No Abstract]   [Full Text] [Related]  

  • 2. [Guanfacine (Estulic) in the monotherapy of essential hypertension, grades I and II, according to WHO].
    Mayer K; Lupínek Z; Janousek S; Podrouzková B
    Cas Lek Cesk; 1984 Oct; 123(43):1306-11. PubMed ID: 6391673
    [No Abstract]   [Full Text] [Related]  

  • 3. [Use of estulic in patients with arterial hypertension].
    Kukes VG; Spasskiĭ AV; Alkhazov AI; Rudakov AG; Zisel'man SB
    Sov Med; 1985; (12):57-61. PubMed ID: 3913006
    [No Abstract]   [Full Text] [Related]  

  • 4. [Antihypertensive therapy with guanfacine. A multicenter study with Estulic-Wander 1mg. Determinants of effectiveness and tolerance].
    Schäfer N; Knaup G
    Med Welt; 1983 Feb; 34(5):158-61. PubMed ID: 6341756
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical trial of a new antihypertensive preparation: guanfacine].
    Rengo F; Ricciardelli B; Spirito G; Volpe M; Morrone G; Trimarco B; Condorelli M
    Boll Soc Ital Cardiol; 1979; 24(10):1097-102. PubMed ID: 400394
    [No Abstract]   [Full Text] [Related]  

  • 6. [Circadian changes in arterial blood pressure and hemodynamics and the morphofunctional state of the myocardium in patients with hypertension during long-term treatment with estulic].
    Komarov FI; Ol'binskaia LI; Iamshchikov SN
    Klin Med (Mosk); 1990 Feb; 68(2):58-61. PubMed ID: 2186218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of arterial hypertension with a single daily dose of guanfacine].
    Jardim PC; Rassi S; Lopes M; Simioni PR; Guimarães E; Maranhão MF; Porto CC
    Arq Bras Cardiol; 1984 Nov; 43(5):365-9. PubMed ID: 6399438
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hypotensive and hemodynamic effects of guanfacine in arterial hypertension].
    Erina EV; Beliakova EV; Charyev KhZ; Panfilov VV
    Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1989; 12(1):63-7. PubMed ID: 2663029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Guanfacine in primary arterial hypertension: a long-term open clinical study].
    Román O; Valenzuela MA; Salazar R
    Rev Med Chil; 1982 Dec; 110(12):1179-84. PubMed ID: 6764015
    [No Abstract]   [Full Text] [Related]  

  • 10. Guanfacine (Estulic) in the treatment of hypertension.
    Cor Vasa; 1987; 29(4 Suppl 1):1-52. PubMed ID: 3315446
    [No Abstract]   [Full Text] [Related]  

  • 11. [Guanfacine in the treatment of arterial hypertension. Apropos of 471 cases in a hospital milieu].
    Carette B
    Ann Cardiol Angeiol (Paris); 1984; 33(2):123-6. PubMed ID: 6143529
    [No Abstract]   [Full Text] [Related]  

  • 12. A comparative study of a new alpha-adrenoceptor agonist, guanfacine and alpha-methyldopa in the treatment of hypertension.
    Joshi RC; De A; Cameron EG
    Br J Clin Pract; 1984 Feb; 38(2):66-7, 71. PubMed ID: 6142723
    [No Abstract]   [Full Text] [Related]  

  • 13. Examination of the antihypertensive action of long-term estulic (Egis-Sandoz) treatment.
    Zeher M; Antal L; Azad AQ; Szegedi G
    Ther Hung; 1988; 36(3):103-8. PubMed ID: 3074520
    [No Abstract]   [Full Text] [Related]  

  • 14. Guanfacine in the treatment of hypertensives with a pronounced response to exercise and diabetes mellitus.
    Dvorák I; Podrouzková B; Kocourková J; Kubesová H; Spác J; Nĕmcová H; Blaha M
    Cor Vasa; 1987; 29(4 Suppl 1):30-6. PubMed ID: 3315448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose guanfacine and methyldopa in mild essential hypertension. A multiple centre study.
    Viskoper RJ; Laszt A; Paran E; Ben Ari J; Goren Y; Modan M
    Neth J Med; 1987 Aug; 31(1-2):58-65. PubMed ID: 3309693
    [No Abstract]   [Full Text] [Related]  

  • 16. [A clinical study of guanfacine in the treatment of arterial hypertension].
    Kheder A; Souilem J; Hassine L; Ben Maiz H; Ben Moussa F; Ben Ayed H
    Tunis Med; 1987 Nov; 65(11):709-12. PubMed ID: 3332951
    [No Abstract]   [Full Text] [Related]  

  • 17. Hemodynamic effects of guanfacine in essential hypertension.
    Feldstein CA; Cohen AA; Sabaris RP; Burucúa JE
    Clin Ther; 1984; 6(3):325-34. PubMed ID: 6373009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guanfacine: a new centrally-acting antihypertensive agent.
    Beevers DG; Bloxham CA; Walker JM
    Pharmatherapeutica; 1981; 2(8):513-6. PubMed ID: 7019931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The place of guanfacine in the treatment of essential arterial hypertension].
    Koaté P; Diouf S; Sylla M; Sarr M; Ba SA
    Dakar Med; 1983; 28(2):321-36. PubMed ID: 6360603
    [No Abstract]   [Full Text] [Related]  

  • 20. Small and large doses of guanfacine (Estulic Sandoz) in the treatment of hypertension.
    Mayer O; Polívková H
    Cor Vasa; 1987; 29(4 Suppl 1):37-41. PubMed ID: 3315449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.